

FINANCIAL INFORMATION

You should read the following discussion and analysis in conjunction with audited consolidated financial information included in “Appendix I — Accountants’ Report” to this document, together with the accompanying notes. Our consolidated financial information has been prepared in accordance with IFRS Accounting Standards, which may differ in material aspects from generally accepted accounting principles in other jurisdictions. You should read the entire Accountants’ Report and not merely rely on the information contained in this section.

The following discussion and analysis contain forward-looking statements that reflect the current views with respect to future events and financial performance. These statements are based on assumptions and analysis made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate under the circumstances. However, whether the actual outcome and developments will meet our expectations and predictions depends on a number of risks and uncertainties over which we do not have control. For details, see “Forward-looking Statements” and “Risk Factors” in this document.

OVERVIEW

We are a leading integrated temperature-control supply chain service provider in China for the pharmaceutical and life science industry. With a core focus on temperature-control supply chain services for clinical trials, we also extend our business to temperature-control supply chain services for commercial medical products, as well as the R&D and manufacturing of temperature-control equipment and materials. According to Frost & Sullivan, based on the revenue in 2025, we were the largest temperature-control supply chain service provider for pharmaceutical and life science industry in China, and the only Chinese company among the global top 10 clinical trial temperature-control supply chain service providers.

We have achieved steady financial growth during the Track Record Period. Our revenue increased from RMB614.2 million in 2023 to RMB654.5 million in 2024, and further increased to RMB727.6 million in 2025. For the four months ended April 30, 2026, our revenue increased to RMB256.4 million, as compared to RMB236.8 million for the same period in 2025. Our gross profit increased from RMB202.3 million in 2023 to RMB215.5 million in 2024, with a stable gross profit margin of 32.9%, and further increased to RMB268.8 million in 2025, with gross profit margin improving to 36.9%. For the four months ended April 30, 2026, our gross profit increased to RMB97.2 million, with a gross profit margin of 37.9%, as compared to RMB88.0 million for the same period in 2025, with a gross profit margin of 37.2%. In 2023, 2024, 2025 and for the four months ended April 30, 2025 and 2026, our profit for the year/period amounted to RMB92.0 million, RMB26.4 million, RMB139.0 million, RMB49.7 million and RMB45.2 million, respectively. Excluding the impact of these share-based payments, [REDACTED] expenses and the corresponding tax income, our adjusted net profit (non-IFRS measure) amounted to RMB97.5 million, RMB100.5 million, RMB152.0 million, RMB54.4 million and RMB55.7 million in 2023, 2024, 2025 and for the four months ended April 30, 2025 and 2026, respectively. Our corresponding adjusted net profit margin (non-IFRS measure) was 15.9%, 15.4%, 20.9%, 23.0% and 21.7% for each respective period during the Track Record Period. Please see “— Non-IFRS Measure” for details.

FINANCIAL INFORMATION

MAJOR FACTORS AFFECTING OUR RESULTS OF OPERATIONS

Growing Clinical Trial Temperature-Control Supply Chain Services Markets and Upstream Markets

Our financial performance is significantly influenced by the development of the overall temperature-control supply chain market for the pharmaceutical and life science industry. In recent years, demand for high-standard temperature-control supply chain services has continued to expand, driven by the increasing scale and complexity of clinical trials and the growing circulation of temperature-sensitive pharmaceutical products. According to Frost & Sullivan, the global market for temperature-control supply chain services for clinical trials has increased from RMB21.4 billion in 2020 to RMB39.1 billion in 2025 in terms of revenue, at a CAGR of 12.8%, and is expected to further expand to RMB62.4 billion by 2030, at a CAGR of 9.7% from 2026 to 2030. In China, the corresponding market grew from RMB2.0 billion in 2020 to RMB4.0 billion in 2025, at a CAGR of 14.9%, and is projected to reach RMB7.3 billion by 2030, at a CAGR of 12.7% from 2026 to 2030. While the sustained expansion of the market provides a favorable demand environment, the industry is also subject to evolving regulatory requirements and intensifying competition, which may affect pricing, cost structures and service delivery efficiency.

Demand for temperature-control supply chain services is closely linked to developments in the upstream pharmaceutical industry, prevailing market conditions and regulatory policies. R&D investments by pharmaceutical companies have become a key growth driver of the pharmaceutical industry. According to Frost & Sullivan, global R&D expenditure by pharmaceutical companies increased from US\$204.8 billion in 2020 to US\$277.6 billion in 2024, representing a CAGR of 7.9%. This spending is expected to further grow to US\$392.9 billion by 2030, demonstrating a CAGR of 6.0% from 2024 to 2030. However, pharmaceutical R&D activity is sensitive to macroeconomic conditions, financing cycles and regulatory policies, and fluctuations in funding availability or changes in cross-border regulatory requirements may affect the timing and scale of demand for clinical trial and commercialization-stage supply chain services.

Our Ability to Continuously Meet Customer Demand

Our ability to continuously satisfy customer demand is critical to our sustained growth. As a leading integrated temperature-control supply chain service provider in China for the pharmaceutical and life science industry, our revenue growth will largely depend on deepening existing customer relationships and acquiring new customers through delivering specialized, integrated, and diversified services effectively.

To proactively address evolving market needs, we continuously invest in technical innovation, optimize business processes, and advance temperature-control technologies. Additionally, we maintain close communication with customers to anticipate emerging requirements and tailor our solutions accordingly. The integration of technologies such as

FINANCIAL INFORMATION

packaging and temperature-control technologies, further enhances our responsiveness and service quality. Our capability to continuously meet and anticipate customer demands is a key factor in maintaining our competitive position and ensuring sustainable profitability.

Our Ability to Grow Our Customer Base

We have a diverse customer base, including Chinese and multinational biopharmaceutical companies, commercial pharmaceutical and medical device companies, their appointed contract service organizations, such as CROs and CDMOs, central laboratories and research institutions. In addition, customers of our temperature-control products also include transportation and logistics providers. During the Track Record Period, we had served over 7,000 customers largely in biopharmaceutical and biotechnology industry. We have established long-term collaborations with a number of leading pharmaceutical companies. According to Frost & Sullivan, our customer base during the Track Record Period covered 100% of the top 20 pharmaceutical companies in China and 50% of the global top 20 pharmaceutical companies measured by R&D expenses in 2025. Among our top five customers in each period during the Track Record Period, 87% had maintained collaboration with us for over eight years, highlighting the depth and stability of our customer relationship. Our results of operations depend largely on our ability to retain existing customers and to acquire new customers. Our ability to attract and retain customers is affected by our brand image, service quality, service offerings, geographic footprint and capacity. Our comprehensive and high-quality service offerings and strong scientific and technical expertise have enabled us to enter into new service contracts with existing customers and attract new customers.

Expansion of Temperature-control Supply Chain Service Network

Our financial performance is impacted by our continued efforts to expand the scale and geographic coverage of our supply chain service network in China and selected overseas markets. Network expansion is an integral part of our growth strategy and typically involves upfront investments, including the establishment of supply chain infrastructure, development of local service capabilities, and integration of new facilities and personnel into our existing systems. Our supply chain service network expansion requires upfront investments. These investments may be incurred ahead of revenue generation and, depending on the pace of market development and utilization levels, may affect our cost structure and operating margins.

We manage the pace and scope of network expansion in a disciplined manner, with a focus on long-term utilization and sustainable returns. As we deepen market penetration and enhance service density within existing regions, we expect improved capacity utilization, operating leverage and efficiency across our network. In addition, our standardized operating processes, digitalized systems and accumulated project experience enable us to replicate service capabilities more efficiently over time, which helps moderate incremental costs as the network expands.

FINANCIAL INFORMATION

Our Ability to Manage Costs to Improve Operating Efficiency

During the Track Record Period, we continued to strengthen cost control and operating efficiency across our service and products sales and business operations. Our cost of sales increased from RMB411.9 million in 2023 to RMB439.0 million in 2024, and it increased from RMB148.8 million in the four months ended April 30, 2025 to RMB159.2 million for the same period in 2026, broadly in line with revenue growth during the same period. While our revenue increased by 11.2% from RMB654.5 million in 2024 to RMB727.6 million in 2025, our cost of sales increased by 4.5% during the same year, reflecting the economies of scale and operating leverage achieved as our business expanded.

Going forward, as we expand our customer base and continue to diversify our service and product offerings, our ability to control cost of sales and operating expenses will be critical to improving profitability. We expect to achieve further cost efficiencies through continued digitalization of operations and management, ongoing optimization of our service and product mix, and further standardization and streamlining of operational processes. These measures are expected to control costs, and to support sustained improvement in our profit margin profile.

BASIS OF PREPARATION

Our historical financial information has been prepared in accordance with applicable IFRS Accounting Standards as issued by the International Accounting Standards Board (“IASB”). The historical financial information has been prepared under the historical cost convention except for certain financial instruments which have been measured at fair value at the end of each year during the Track Record Period.

MATERIAL ACCOUNTING POLICIES AND ESTIMATES

We have identified certain accounting policies that are material to the preparation of our consolidated financial statements. Some of our accounting policies involve subjective assumptions and estimates, as well as complex judgments relating to accounting items. We set out below some of the accounting policies and estimates that we believe are of critical importance to us or involve the most significant estimates and judgments used in the preparation of our financial statements. Our judgments and estimates, which are important for understanding our financial condition and results of operations, are set out in further detail in Note 3 to the Accountants’ Report in Appendix I to this document. When reviewing our financial statements, you should consider (i) our selection of key accounting policies, (ii) the judgment and other uncertainties affecting the application of such policies, and (iii) the results to changes in conditions and assumptions. We believe that the material accounting policy information and estimates as detailed in Note 2 and Note 3 to the Accountants’ Report in Appendix I to this document are critical and involve the most important estimates and judgments we used in preparing our financial statements.

FINANCIAL INFORMATION

DESCRIPTION OF SELECTED COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE PROFIT OR LOSS

The following table sets forth our consolidated statements of comprehensive profit or loss for the periods indicated:

	For the Year ended December 31,						For the Four Months ended April 30,			
	2023		2024		2025		2025		2026	
	Amount	%	Amount	%	Amount	%	Amount (unaudited)	%	Amount	%
(RMB in thousands, except percentages)										
Revenue	614,186	100.0	654,489	100.0	727,574	100.0	236,815	100.0	256,411	100.0
Cost of sales	(411,933)	(67.1)	(439,031)	(67.1)	(458,812)	(63.1)	(148,817)	(62.8)	(159,165)	(62.1)
Gross profit	202,253	32.9	215,458	32.9	268,762	36.9	87,998	37.2	97,246	37.9
Other net income	13,040	2.1	17,397	2.7	16,168	2.2	5,027	2.1	6,286	2.5
Selling and marketing expenses	(24,726)	(4.0)	(38,781)	(5.9)	(31,343)	(4.3)	(8,711)	(3.7)	(10,765)	(4.2)
Administrative expenses	(62,068)	(10.1)	(121,742)	(18.6)	(68,524)	(9.4)	(20,312)	(8.6)	(32,344)	(12.6)
Research and development costs	(21,860)	(3.6)	(22,875)	(3.5)	(23,113)	(3.2)	(6,933)	(2.9)	(7,839)	(3.1)
(Provision for)/reversal of impairment loss on trade and other receivables	(961)	(0.2)	(1,567)	(0.2)	246	–	(953)	(0.4)	(1,216)	(0.5)
Profit from operations	105,678	17.2	47,890	7.3	162,196	22.3	56,116	23.7	51,368	20.0
Finance costs	(4,221)	(0.7)	(3,687)	(0.6)	(2,660)	(0.4)	(1,025)	(0.4)	(770)	(0.3)
Share of profits of associates	1,852	0.3	253	–	304	–	(67)	–	(373)	(0.1)
Profit before taxation	103,309	16.8	44,456	6.8	159,840	22.0	55,024	23.2	50,225	19.6
Income tax	(11,276)	(1.8)	(18,060)	(2.8)	(20,825)	(2.9)	(5,284)	(2.2)	(4,983)	(1.9)
Profit for the year/period	92,033	15.0	26,396	4.0	139,015	19.1	49,740	21.0	45,242	17.6
Attributable to:										
Equity shareholders of the										
Company	93,373	15.2	27,550	4.2	139,166	19.1	49,989	21.1	44,938	17.5
Non-controlling interests	(1,340)	(0.2)	(1,154)	(0.2)	(151)	–	(249)	(0.1)	304	0.1
Profit for the year/period	92,033	15.0	26,396	4.0	139,015	19.1	49,740	21.0	45,242	17.6

NON-IFRS MEASURE

To supplement our consolidated financial statements which are presented in accordance with IFRS Accounting Standards, we also use adjusted net profit (non-IFRS measure) and adjusted net profit margin (non-IFRS measure) as additional financial measures, which are not required by, or presented in accordance with IFRS Accounting Standards. We believe that such non-IFRS measure facilitates comparisons of operating performance from period to period and company to company by eliminating potential impacts of items. We also believe that such

FINANCIAL INFORMATION

measures provide useful information to investors and others in understanding and evaluating our consolidated results of operations in the same manner as they help our management. However, our presentation of such non-IFRS measure may not be comparable to similarly titled measures presented by other companies. The use of such non-IFRS measure has limitations as an analytical tool, and you should not consider it in isolation from, or as substitute for analysis of, our results of operations or financial condition as reported under IFRS Accounting Standards.

We define adjusted net profit for the year/period (non-IFRS measure) as profit for the year/period excluding share-based payments, [REDACTED] expenses and effect of corresponding income tax. Share-based payments are non-cash in nature and do not result in cash outflow and [REDACTED] expenses are expenses relates to previous A-share listing attempt and the [REDACTED] and are non-recurring in nature. Effect of corresponding income tax represents the tax impact associated with [REDACTED] expenses. We define adjusted net profit margin (non-IFRS measure) as adjusted net profit (non-IFRS measure) divided by revenue for the same year/period and multiplied by 100%.

The following table reconciles our adjusted net profit (non-IFRS measure) and adjusted net profit margin (non-IFRS measure) for the periods indicated:

	For the Year ended December 31,			For the Four Months ended April 30,	
	2023	2024	2025	2025	2026
				<i>(unaudited)</i>	
				<i>(RMB in thousands, except percentages)</i>	
Profit for the year/period .	92,033	26,396	139,015	49,740	45,242
Add:					
Share-based payments . . .	1,598	72,123	4,639	4,639	—
[REDACTED] expenses .					
In connection with					
previous A-share					
listing attempt ⁽¹⁾	[REDACTED]	[REDACTED]	—	—	—
In connection with the					
[REDACTED]	—	—	[REDACTED]	—	[REDACTED]
Effect of corresponding					
income tax	(1,291)	(650)	(2,627)	—	(3,375)
Adjusted net profit					
(non-IFRS measure) . .	97,503	100,470	151,984	54,379	55,696
Adjusted net profit margin					
(non-IFRS measure)					
(%)	15.9	15.4	20.9	23.0	21.7

Note:

- (1) [REDACTED] expenses in connection with previous A-share listing attempt refer to expenses incurred for our previous listing attempt, for details of which see “History, Development and Corporate Structure — Previous A-share Listing Attempt and Reasons for the [REDACTED].”

FINANCIAL INFORMATION

Revenue

During the Track Record Period, our revenue was derived from the provision of temperature-control supply chain services and sales of temperature-control products. The following table sets forth a breakdown of our revenue for the periods indicated:

	For the Year ended December 31,						For the Four Months ended April 30,			
	2023		2024		2025		2025		2026	
	Amount	%	Amount	%	Amount	%	Amount	%	Amount	%
	(unaudited)									
	(RMB in thousands, except percentages)									
Temperature-control										
supply chain services										
– for clinical trials	508,097	82.7	542,011	82.8	597,899	82.1	193,641	81.7	204,593	79.8
– for commercial medical										
products	99,414	16.2	98,184	15.0	105,039	14.5	32,111	13.6	43,627	17.0
	<u>607,511</u>	<u>98.9</u>	<u>640,195</u>	<u>97.8</u>	<u>702,938</u>	<u>96.6</u>	<u>225,752</u>	<u>95.3</u>	<u>248,220</u>	<u>96.8</u>
Sales of temperature-										
control products	<u>6,675</u>	<u>1.1</u>	<u>14,294</u>	<u>2.2</u>	<u>24,636</u>	<u>3.4</u>	<u>11,063</u>	<u>4.7</u>	<u>8,191</u>	<u>3.2</u>
Total	<u><u>614,186</u></u>	<u><u>100.0</u></u>	<u><u>654,489</u></u>	<u><u>100.0</u></u>	<u><u>727,574</u></u>	<u><u>100.0</u></u>	<u><u>236,815</u></u>	<u><u>100.0</u></u>	<u><u>256,411</u></u>	<u><u>100.0</u></u>

Revenue by Business Lines

We provide temperature-control supply chain services for pharmaceutical and life science products across their full lifecycle, from pre-clinical, clinical trials through commercialization. Specifically, our temperature-control supply chain services primarily cover (i) supply chain services for clinical trial activities; and (ii) supply chain services for commercial-stage medical products, including both pharmaceutical drugs and medical devices.

Temperature-Control Supply Chain Services for Clinical Trials. We provide a comprehensive range of temperature-control supply chain services to support clinical trial activities. During the Track Record Period, revenue from our clinical trial temperature-control supply chain services witnessed sustained growth, increasing by 6.7% from RMB508.1 million in 2023 to RMB542.0 million in 2024, and further increased by 10.3% to RMB597.9 million in 2025, and it increased by 5.7% from RMB193.6 million for the four months ended April 30, 2025 to RMB204.6 million for the same period in 2026. Clinical trial temperature-control supply chain services represent our core business. During the Track Record Period, revenue from this business consistently accounted for the majority of our revenue, representing 82.7%, 82.8%, 82.1%, 81.7% and 79.8% of our revenue in 2023, 2024, 2025 and for the four months ended April 30, 2025 and 2026, respectively.

FINANCIAL INFORMATION

Temperature-Control Supply Chain Services for Commercial Medical Products. We also provide temperature-control supply chain services for commercial-stage medical products, including pharmaceutical drugs and medical devices. During the Track Record Period, revenue from our commercial medical products supply chain services remained relatively stable at RMB99.4 million in 2023 and RMB98.2 million in 2024, and it increased by 7.0% to RMB105.0 million in 2025, and it increased by 35.9% from RMB32.1 million in the four months ended April 30, 2025 to RMB43.6 million for the same period in 2026. Revenue from this business accounted for 16.2%, 15.0%, 14.5%, 13.6% and 17.0% of our revenue in 2023, 2024, 2025 and for the four months ended April 30, 2025 and 2026, respectively.

Sales of Temperature-Control Products. Our sales of temperature-control products primarily comprise temperature-control parcels and containers, as well as our in-house developed core components, including VIPs and PCM packs. During the Track Record Period, revenue from sales of temperature-control products recorded sustained growth, increasing by 114.1% from RMB6.7 million in 2023 to RMB14.3 million in 2024, and further increasing by 72.4% to RMB24.6 million in 2025, and it decreased by 26.0% from RMB11.1 million in the four months ended April 30, 2025 to RMB8.2 million for the same period in 2026. Revenue from this business accounted for 1.1%, 2.2%, 3.4%, 4.7% and 3.2% of our revenue in 2023, 2024, 2025 and for the four months ended April 30, 2025 and 2026, respectively.

Revenue by Geographic Coverage

During the Track Record Period, a substantial majority of our revenue was generated from Chinese Mainland. The following table sets forth a geographic breakdown of our revenue based on the incorporation place of our customers, in an absolute amount and as a percentage of our revenue, for the periods indicated.

	For the Year ended December 31,						For the Four Months ended April 30,			
	2023		2024		2025		2025		2026	
	Amount	%	Amount	%	Amount	%	Amount	%	Amount	%
	(unaudited)									
	(RMB in thousands, except percentages)									
Chinese Mainland	594,051	96.7	606,972	92.7	674,821	92.7	214,547	90.6	234,582	91.5
Overseas ⁽¹⁾	20,135	3.3	47,517	7.3	52,753	7.3	22,268	9.4	21,829	8.5
Total	614,186	100.0	654,489	100.0	727,574	100.0	236,815	100.0	256,411	100.0

Note:

(1) Primarily including revenue from North America, Europe, Asia Pacific regions.

Cost of Sales

Our cost of sales primarily consisted of (i) staff costs, primarily representing the payroll and related expenses for our employees engaged in the operation of our services; (ii) supply chain service fulfillment costs primarily representing the costs incurred by the third-party service providers for transportation and outsourced delivery service; (iii) depreciation and

FINANCIAL INFORMATION

amortization; (iv) consumables and labeling costs, primarily representing the procurement costs of thermometers and label paper; (v) vehicle expenses, primarily representing the fuel, toll and maintenance fees in relation to our vehicles; (vi) premises-related expenses in relation to the rental and utility expenses of our warehouses and regional operational centers and sites; (vii) share-based payments; and (viii) others, which primarily including travel and accommodation costs, and material costs and processing service fees incurred in the production of temperature-control products. The following table sets forth a breakdown of our cost of sales by nature, in an absolute amount and as a percentage of our total cost of sales, for the periods indicated:

	For the Year ended December 31,						For the Four Months ended April 30,			
	2023		2024		2025		2025		2026	
	Amount	%	Amount	%	Amount	%	Amount	%	Amount	%
	(unaudited)									
	(RMB in thousands, except percentages)									
Staff costs	134,235	32.6	135,678	30.9	143,248	31.2	44,969	30.2	50,912	32.0
Supply chain service fulfillment costs	114,307	27.7	131,179	29.9	143,133	31.2	46,589	31.3	54,622	34.3
Depreciation and amortization	58,007	14.1	65,974	15.0	57,139	12.5	20,549	13.8	16,194	10.2
Consumables and labeling costs	33,178	8.1	31,705	7.2	38,840	8.5	10,428	7.0	13,016	8.2
Vehicle expenses	33,272	8.1	34,375	7.8	34,813	7.6	11,116	7.5	11,587	7.3
Premises-related expenses	16,969	4.1	16,330	3.7	15,568	3.4	5,111	3.4	4,722	3.0
Share-based payments	229	0.1	1,474	0.3	800	0.2	800	0.5	–	–
Others	21,736	5.2	22,316	5.2	25,271	5.4	9,255	6.3	8,112	5.0
Total	411,933	100.0	439,031	100.0	458,812	100.0	148,817	100.0	159,165	100.0

The following table sets forth a breakdown of our cost of sales by business lines, in an absolute amount and as a percentage of our total cost of sales, for the periods indicated:

	For the Year ended December 31,						For the Four Months ended April 30,			
	2023		2024		2025		2025		2026	
	Amount	%	Amount	%	Amount	%	Amount	%	Amount	%
	(unaudited)									
	(RMB in thousands, except percentages)									
Temperature-control supply chain services	407,448	98.9	429,495	97.8	446,656	97.4	143,693	96.6	155,515	97.7
Sales of temperature-control products	4,485	1.1	9,536	2.2	12,156	2.6	5,124	3.4	3,650	2.3
Total	411,933	100.0	439,031	100.0	458,812	100.0	148,817	100.0	159,165	100.0

FINANCIAL INFORMATION

Gross Profit and Gross Profit Margin

Our gross profit increased by 6.5% from RMB202.3 million in 2023 to RMB215.5 million in 2024, and it increased by 24.7% to RMB268.8 million in 2025, and it increased by 10.5% from RMB88.0 million for the four months ended April 30, 2025 to RMB97.2 million for the same period in 2026. Our gross profit margin was 32.9%, 32.9%, 36.9%, 37.2% and 37.9% in 2023, 2024, 2025 and for the four months ended April 30, 2025 and 2026, respectively. The following table sets forth the breakdown of our gross profit in absolute amounts and gross profit margin in percentages by business lines for the periods indicated:

	For the Year ended December 31,						For the Four Months ended April 30,			
	2023		2024		2025		2025		2026	
	Gross profit	Gross profit margin	Gross profit	Gross profit margin	Gross profit	Gross profit margin	Gross profit	Gross profit margin	Gross profit	Gross profit margin
	Amount	%	Amount	%	Amount	%	Amount	%	Amount	%
	(unaudited)									
	(RMB in thousands, except percentages)									
Temperature-control supply chain services	200,063	32.9	210,700	32.9	256,282	36.5	82,059	36.3	92,705	37.3
Sales of temperature-control products	2,190	32.8	4,758	33.3	12,480	50.7	5,939	53.7	4,541	55.4
Total gross profit/gross profit margin	202,253	32.9	215,458	32.9	268,762	36.9	87,998	37.2	97,246	37.9

Other Net Income

Our other net income primarily consisted of (i) net realized and unrealized gain on other financial assets, which were primarily held for asset management purposes; (ii) government grants, mainly representing subsidies received from local governments in China; (iii) net (losses)/gains on disposal of property, plant and equipment; (iv) interest income from bank deposits; and (v) net foreign exchange gains or losses. The following table sets forth a breakdown of our other net income for the periods indicated:

	For the Year ended December 31,			For the Four Months ended April 30,	
	2023	2024	2025	2025	2026
	(unaudited)				
	(RMB in thousands)				
Net realized and unrealized gain on other financial assets	7,357	9,947	11,201	3,792	2,975
Government grants	4,549	7,097	3,888	185	3,339
Net (losses)/gains on disposal of property, plant and equipment . . .	(824)	(824)	1,084	852	111
Interest income	2,888	1,332	617	188	265
Impairment loss on intangible assets	(1,471)	—	—	—	—
Net foreign exchange gains/(losses)	541	(155)	(622)	10	(404)
Total other net income . .	13,040	17,397	16,168	5,027	6,286

FINANCIAL INFORMATION

Selling and Marketing Expenses

Our selling and marketing expenses primarily consisted of (i) staff costs; (ii) marketing and promotion expenses; (iii) depreciation and amortization; (iv) share-based payments; and (v) others, primarily including travel expenses, and office and premises expenses related to sales activities. The following table sets forth a breakdown of our selling and marketing expenses, in an absolute amount and as a percentage of our total selling and marketing expenses, for the periods indicated:

	For the Year ended December 31,						For the Four Months ended April 30,			
	2023		2024		2025		2025		2026	
	Amount	%	Amount	%	Amount	%	Amount (unaudited)	%	Amount	%
(RMB in thousands, except percentages)										
Staff costs	20,157	81.5	22,875	59.0	26,065	83.2	7,205	82.7	8,484	78.8
Marketing and promotion expenses	2,355	9.5	3,217	8.3	2,840	9.1	861	9.9	1,645	15.3
Depreciation and amortization	411	1.7	537	1.4	353	1.1	126	1.4	139	1.3
Share-based payments . . .	517	2.1	9,628	24.8	–	–	–	–	–	–
Others	1,286	5.2	2,524	6.5	2,085	6.6	519	6.0	497	4.6
Total	24,726	100.0	38,781	100.0	31,343	100.0	8,711	100.0	10,765	100.0

Administrative Expenses

Our administrative expenses primarily consisted of (i) staff costs; (ii) travel and office expenses; (iii) share-based payments; (iv) depreciation and amortization; (v) professional service fees, primarily relating to audit service, legal service and other professional services; (vi) [REDACTED] expenses in connection with previous A-share listing attempt; (vii) [REDACTED] expenses in connection with the [REDACTED]; and (viii) others, primarily including taxes and surcharges, bank surcharges and others. The following table sets forth a breakdown of our administrative expenses, in an absolute amount and as a percentage of our total administrative expenses, for the periods indicated:

	For the Year ended December 31,						For the Four Months ended April 30,			
	2023		2024		2025		2025		2026	
	Amount	%	Amount	%	Amount	%	Amount (unaudited)	%	Amount	%
(RMB in thousands, except percentages)										
Staff costs	34,147	55.0	38,054	31.3	37,749	55.1	12,433	61.2	14,121	43.7
Travel and office expenses	5,952	9.6	6,627	5.4	5,909	8.6	957	4.7	1,384	4.3
Share-based payments . . .	852	1.4	61,021	50.1	3,839	5.6	3,839	18.9	–	–
Depreciation and amortization	5,384	8.7	3,895	3.2	3,828	5.6	1,269	6.2	1,478	4.6
Professional service fees . .	6,338	10.2	6,656	5.5	3,594	5.2	991	4.9	641	2.0
[REDACTED] expenses in connection with previous A-share listing attempt . .	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	–	–	–	–	–	–
[REDACTED] expenses in connection with the [REDACTED]	–	–	–	–	[REDACTED]	[REDACTED]	–	–	[REDACTED]	[REDACTED]
Others	4,232	6.8	2,888	2.4	2,648	3.9	823	4.1	891	2.6
Total	62,068	100.0	121,742	100.0	68,524	100.0	20,312	100.0	32,344	100.0

FINANCIAL INFORMATION

Research and Development Costs

Our research and development costs primarily consisted of (i) staff costs, (ii) depreciation and amortization; (iii) others, primarily including R&D materials expenses, equipment testing costs, travel and office expenses incurred by R&D staff. The following table sets forth a breakdown of our research and development costs, in an absolute amount and as a percentage of our total research and development costs, for the periods indicated:

	For the Year ended December 31,						For the Four Months ended April 30,			
	2023		2024		2025		2025		2026	
	Amount	%	Amount	%	Amount	%	Amount	%	Amount	%
	(unaudited)									
	(RMB in thousands, except percentages)									
Staff costs	19,021	87.0	20,281	88.7	20,082	86.9	6,138	88.5	6,992	89.2
Depreciation and amortization	1,029	4.7	1,328	5.8	1,347	5.8	463	6.7	484	6.2
Others	1,810	8.3	1,266	5.5	1,684	7.3	332	4.8	363	4.6
Total	21,860	100.0	22,875	100.0	23,113	100.0	6,933	100.0	7,839	100.0

Provision for/Reversal of Impairment Loss on Trade and Other Receivables

We recorded impairment losses on trade and other receivables primarily due to the expected credit losses on trade receivables arising from the provision of services and sale of goods. In 2023 and 2024, our provision for impairment loss on trade and other receivables amounted to RMB1.0 million and RMB1.6 million, respectively. In 2025, we recorded a reversal of impairment loss on trade and other receivables of RMB0.2 million. For the four months ended April 30, 2025 and 2026, our provision for impairment loss on trade and other receivables amounted to RMB1.0 million and RMB1.2 million, respectively.

Finance Costs

Our finance costs mainly represented the interest on lease liabilities. In 2023, 2024, 2025 and for the four months ended April 30, 2025 and 2026, our finance costs were RMB4.2 million, RMB3.7 million, RMB2.7 million, RMB1.0 million and RMB0.8 million respectively.

Share of Profits of Associates

During the Track Record Period, we held equity interests in ClinsChain (Shanghai) Clinical Services Co., Ltd., Shanghai Becquerel Science & Technology Co., Ltd. and Nera Cold Chain Solutions. For details, see Note 16 to the Accountants’ Report in Appendix I to this document. As a result, we recorded a share of profits of associates of RMB1.9 million, RMB0.3 million, RMB0.3 million, RMB0.1 million and RMB0.4 million in 2023, 2024 and 2025 and for the four months ended April 30, 2025 and 2026, respectively.

FINANCIAL INFORMATION

Income Tax

We recorded income tax of RMB11.3 million, RMB18.1 million, RMB20.8 million, RMB5.3 million and RMB5.0 million respectively, in 2023, 2024, 2025 and for the four months ended April 30, 2025 and 2026.

Entities in Chinese Mainland are generally subject to a statutory corporate income tax rate of 25.0%. One of our subsidiaries in Chinese Mainland qualified as high and new technology enterprises enjoyed a preferential corporate income tax rate of 15% for the Track Record Period. In addition, certain of our subsidiaries in Chinese Mainland fulfilled the micro and small enterprises qualification under the PRC corporate income tax system, and therefore were subject to a preferential income tax rate of 20%. The provision for Hong Kong profits tax was calculated at 16.5% of the estimated assessable profits for the period. The income tax rates of the subsidiaries in Belgium, Australia and Singapore were 25%, 25% and 17%, respectively. The subsidiary in the United States of America was subject to a federal income tax rate of 21%, along with state income tax rates ranging from 6.5% to 9.5%.

During the Track Record Period and as of the Latest Practicable Date, we had fulfilled all our tax obligations and did not have any unresolved tax disputes.

RESULTS OF OPERATIONS

Four Months Ended April 30, 2026 Compared with Four Months Ended April 30, 2025

Revenue

Our revenue increased by 8.3% from RMB236.8 million for the four months ended April 30, 2025 to RMB256.4 million for the four months ended April 30, 2026, primarily due to revenue growth of our temperature-control supply chain services for clinical trials and for commercial medical products.

Temperature-Control Supply Chain Services for Clinical Trials. Our revenue from supply chain services for clinical trials increased by 5.7% from RMB193.6 million for the four months ended April 30, 2025 to RMB204.6 million for the four months ended April 30, 2026, primarily attributable to higher service order volume in relation to (i) our temperature-control logistics services; and (ii) business growth of our labeling and storage services.

Temperature-Control Supply Chain Services for Commercial Medical Products. Our revenue from supply chain services for commercial medical products increased by 35.9% from RMB32.1 million for the four months ended April 30, 2025 to RMB43.6 million for the four months ended April 30, 2026, primarily attributable to higher service order volume in relation to our temperature-control logistics services.

FINANCIAL INFORMATION

Sales of Temperature-Control Products. Our revenue from sales of temperature-control products decreased by 26.0% from RMB11.1 million for the four months ended April 30, 2025 to RMB8.2 million for the four months ended April 30, 2026, primarily attributable to fluctuations in customer demand and procurement timing for temperature-control products.

Cost of Sales

Our cost of sales increased by 7.0% from RMB148.8 million for the four months ended April 30, 2025 to RMB159.2 million for the four months ended April 30, 2026, generally in line with the growth in our revenue, which led to an increase in related costs, including staff costs and supply chain service fulfillment costs.

Gross Profit and Gross Profit Margin

As a result of the above, our gross profit increased by 10.5% from RMB88.0 million in the four months ended April 30, 2025 to RMB97.2 million in the four months ended April 30, 2026. Our overall gross profit margin remained relatively stable at 37.2% in the four months ended April 30, 2025 and 37.9% in the four months ended April 30, 2026.

Other Net Income

Our other net income increased by 25.0% from RMB5.0 million for the four months ended April 30, 2025 to RMB6.3 million for the four months ended April 30, 2026, primarily due to an increase in government grants resulting from the subsidies received from local governments in China.

Selling and Marketing Expenses

Our selling and marketing expenses increased by 23.6% from RMB8.7 million for the four months ended April 30, 2025 to RMB10.8 million for the four months ended April 30, 2026, primarily due to (i) an increase of RMB1.3 million in staff costs as a result of the expansion of our selling and marketing team; and (ii) an increase of RMB0.8 million in marketing and promotion expenses attributable to higher expenses incurred for participating in exhibitions and industry events.

Administrative Expenses

Our administrative expenses increased by 59.2% from RMB20.3 million for the four months ended April 30, 2025 to RMB32.3 million for the four months ended April 30, 2026, primarily due to an increase of RMB13.8 million in [REDACTED] expenses in connection with the [REDACTED].

FINANCIAL INFORMATION

Research and Development Costs

Our research and development costs increased by 13.1% from RMB6.9 million for the four months ended April 30, 2025 to RMB7.8 million for the four months ended April 30, 2026, primarily due to an increase of RMB0.9 million in staff costs as a result of the expansion of our research and development team.

Provision for/Reversal of Impairment Loss on Trade and Other Receivables

Our impairment loss on trade receivables increased by 27.6% from RMB1.0 million for the four months ended April 30, 2025 to RMB1.2 million for the four months ended April 30, 2026, primarily due to an increase in the balance of our trade receivables during the period and the proportional increase of the allowance for such receivables.

Finance Costs

Our finance costs represented the interest on lease liabilities. Our finance costs were RMB1.0 million and RMB0.8 million in the four months ended April 30, 2025 and 2026, respectively.

Income Tax

Our income tax amounted to RMB5.3 million for the four months ended April 30, 2025 and RMB5.0 million for the four months ended April 30, 2026, respectively. Accordingly, our effective tax rate (calculated as income tax divided by profit before taxation) was 9.6% and 9.9%, respectively, for the four months ended April 30, 2025 and 2026, respectively.

Profit for the Period

As a result of the above, our profit for the period decreased by 9.0% from RMB49.7 million for the four months ended April 30, 2025 to RMB45.2 million for the four months ended April 30, 2026.

Year Ended December 31, 2025 Compared with Year Ended December 31, 2024

Revenue

Our revenue increased by 11.2% from RMB654.5 million in 2024 to RMB727.6 million in 2025, primarily due to revenue growth across our business lines.

Temperature-Control Supply Chain Services for Clinical Trials. Our revenue from supply chain services for clinical trials increased by 10.3% from RMB542.0 million in 2024 to RMB597.9 million in 2025, primarily attributable to (i) higher service order volume in relation to our temperature-control logistics services; and (ii) business growth of our labeling and storage services.

FINANCIAL INFORMATION

Temperature-Control Supply Chain Services for Commercial Medical Products. Our revenue from supply chain services for commercial medical products increased by 7.0% from RMB98.2 million in 2024 to RMB105.0 million in 2025, primarily attributable to higher service order volume in relation to our temperature-control logistics services.

Sales of Temperature-Control Products. Our revenue from sales of temperature-control products increased by 72.4% from RMB14.3 million in 2024 to RMB24.6 million in 2025, primarily driven by higher sales volumes as a result of our increased overseas sales.

Cost of Sales

Our cost of sales increased by 4.5% from RMB439.0 million in 2024 to RMB458.8 million in 2025 notwithstanding an 11.2% growth in the revenue for the same year. Such modest increase in cost of sales was primarily driven by the economies of scales, improved operation efficiency and evolving service offering portfolio.

Gross Profit and Gross Profit Margin

As a result of the above, our gross profit increased by 24.7% from RMB215.5 million in 2024 to RMB268.8 million in 2025. Our gross profit margin increased from 32.9% in 2024 to 36.9% in 2025.

The improvement in our overall gross profit margin was due to the increased gross profit margin for both of our temperature-control supply chain services and sales of temperature-control products.

Our gross profit margin for the temperature-control supply chain services increased from 32.9% in 2024 to 36.5% in 2025, primarily attributed to the modest growth of costs compared to relatively fast growth of revenue due to the economies of scales and improved operation efficiency as a result of our digitalization, optimized business processes, and evolving service offering portfolio. Specifically, we have devoted to proprietary IT development tailored to our service and operation needs, which has improved our execution accuracy and operational efficiency. For example, our big data algorithm platform for cold chain logistics, which was developed in 2023 and gradually implemented and upgraded since 2024, synergized operational know-how. This platform enabled data-driven recommendations for operational solutions, boosted operational efficiency, and accelerated data analysis for optimization. In addition, our clinical supply chain drug management system and automated identification technology for clinical trial supplies, both initiated in 2023 and progressively implemented and upgraded in 2024 and 2025, improved the efficiency of clinical packaging and labeling and temperature-control storage management. Furthermore, we have maintained cost control alongside revenue growth as our sales volumes increased. In addition, we experienced a rise in the proportion of storage and labeling services which usually carry higher gross profit margin.

FINANCIAL INFORMATION

Our gross profit margin for the sales of temperature-control products increased from 33.3% in 2024 to 50.7% in 2025, primarily attributed to the economies of scales and evolving product mix. Specifically, our revenue from the sales of temperature-control products increased in 2025, which enabled us to achieve greater absorption of fixed costs. Furthermore, we increased the proportion of sales from higher-margin products, such as those with proprietary technology or customized designs, which increased the overall gross margin.

Other Net Income

Our other net income decreased by 7.1% from RMB17.4 million in 2024 to RMB16.2 million in 2025, primarily due to a decrease of RMB3.2 million in government grants primarily due to the one-off subsidy we applied from local governmental institution in 2024, partially offset by an increase of RMB1.9 million in net gains on disposal of property, plant and equipment and an increase of RMB1.3 million of net realized and unrealized gain on other financial assets.

Selling and Marketing Expenses

Our selling and marketing expenses decreased by 19.2% from RMB38.8 million in 2024 to RMB31.3 million in 2025, primarily due to a decrease of RMB9.6 million in share-based payments, partially offset by an increase of RMB3.2 million in staff costs as a result of the expansion of our selling and marketing team.

Administrative Expenses

Our administrative expenses decreased by 43.7% from RMB121.7 million in 2024 to RMB68.5 million in 2025, primarily due to a decrease of RMB57.2 million in share-based payments, partially offset by an increase of RMB11.0 million in [REDACTED] expenses in connection with the [REDACTED].

Research and Development Costs

Our research and development costs remained relatively stable at RMB22.9 million in 2024 and RMB23.1 million in 2025.

Provision for/Reversal of Impairment Loss on Trade and Other Receivables

We recorded an impairment loss on trade and other receivables of RMB1.6 million and a reversal of RMB0.2 million in 2024 and 2025, respectively. The reversal of impairment loss in 2025 was primarily due to the collection of trade and other receivables that had been previously written-off.

FINANCIAL INFORMATION

Finance Costs

Our finance costs mainly represented the interest on lease liabilities. Our finance costs were RMB3.7 million and RMB2.7 million in 2024 and 2025, respectively.

Income Tax

Our income tax amounted to RMB18.1 million and RMB20.8 million in 2024 and 2025, respectively. Accordingly, our effective tax rate (calculated as income tax divided by profit before taxation) was 40.6% and 13.0%, respectively, in 2024 and 2025.

Profit for the Year

As a result of the above, our profit for the year amounted to RMB26.4 million and RMB139.0 million in 2024 and 2025, respectively.

Year Ended December 31, 2024 Compared with Year Ended December 31, 2023

Revenue

Our revenue increased by 6.6% from RMB614.2 million in 2023 to RMB654.5 million in 2024, primarily due to revenue growth of our temperature-control supply chain services for clinical trials and sales of temperature-control products.

Temperature-Control Supply Chain Services for Clinical Trials. Our revenue from supply chain services for clinical trials increased 6.7% from RMB508.1 million in 2023 to RMB542.0 million in 2024, primarily attributable to higher service order volume in relation to our temperature-control logistics services.

Temperature-Control Supply Chain Services for Commercial Medical Products. Our revenue from supply chain services for commercial medical products remained relatively stable at RMB99.4 million in 2023 and RMB98.2 million in 2024.

Sales of Temperature-Control Products. Our revenue from sales of temperature-control products increased by 114.1% from RMB6.7 million in 2023 to RMB14.3 million in 2024, primarily driven by higher sales volumes as a result of our increased overseas sales.

Cost of Sales

Our cost of sales increased by 6.6% from RMB411.9 million in 2023 to RMB439.0 million in 2024, generally in line with the growth in our service volume and product sales, which led to a modest increase in related costs, including staff costs, supply chain service fulfillment costs and vehicle expenses.

FINANCIAL INFORMATION

Gross Profit and Gross Profit Margin

As a result of the above, our gross profit increased by 6.5% from RMB202.3 million in 2023 to RMB215.5 million in 2024. Our overall gross profit margin and gross profit margin for each of our temperature-control supply chain services and sales of temperature-control products remained relatively stable in 2023 and 2024.

Other Net Income

Our other net income increased by 33.4% from RMB13.0 million in 2023 to RMB17.4 million in 2024, primarily due to the increases in government grants and net realized and unrealized gain on other financial assets, partially offset by the decrease in the interest income.

Selling and Marketing Expenses

Our selling and marketing expenses increased by 56.8% from RMB24.7 million in 2023 to RMB38.8 million in 2024, primarily due to an increase of RMB9.1 million in share-based payments and an increase of RMB2.7 million in staff costs as a result of the expansion of our selling and marketing team.

Administrative Expenses

Our administrative expenses increased by 96.1% from RMB62.1 million in 2023 to RMB121.7 million in 2024, primarily due to an increase of RMB60.2 million in share-based payments.

Research and Development Costs

Our research and development costs increased by 4.6% from RMB21.9 million in 2023 to RMB22.9 million in 2024, primarily due to an increase of RMB1.3 million in staff costs.

Provision for/Reversal of Impairment Loss on Trade and Other Receivables

Our impairment loss on trade and other receivables increased by 63.1% from RMB1.0 million in 2023 to RMB1.6 million in 2024, primarily due to an increase in the balance of our trade receivables in 2024 and the proportional increase of the allowance for such receivables.

Finance Costs

Our finance costs represented the interest on lease liabilities. Our finance costs were RMB4.2 million in 2023 and RMB3.7 million in 2024.

FINANCIAL INFORMATION

Income Tax

Our income tax amounted to RMB11.3 million and RMB18.1 million in 2023 and 2024, respectively. Accordingly, our effective tax rate (calculated as income tax divided by profit before taxation) was 10.9% and 40.6% in the same respective year.

Profit for the Year

As a result of the above, our profit for the year amounted to RMB92.0 million and RMB26.4 million in 2023 and 2024, respectively.

DISCUSSION OF CERTAIN SELECTED ITEMS FROM THE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

The table below sets forth selected information from our consolidated statements of financial position as of the dates indicated:

	As of December 31,			As of April 30,
	2023	2024	2025	2026
	(RMB in thousands)			
Non-current assets				
Property, plant and equipment	96,675	71,578	57,046	63,110
Right-of-use assets	88,413	63,156	46,354	52,542
Intangible assets	6,448	6,450	6,462	6,429
Goodwill	13,753	13,753	13,753	13,753
Interests in associates	20,859	21,112	21,114	20,741
Other financial assets	81,731	84,191	—	—
Deferred tax assets	11,211	12,656	16,958	18,871
Other non-current assets	6,196	4,345	11,597	9,330
Total non-current assets . . .	325,286	277,241	173,284	184,776
Current assets				
Inventories	19,737	19,862	19,785	21,142
Trade and other receivables . .	192,093	228,688	258,407	301,209
Other financial assets	—	1,444	92,404	491,140
Restricted cash	4,003	4,003	5,745	3,817
Cash and cash equivalents . .	450,565	514,932	625,376	207,079
Total current assets	666,398	768,929	1,001,717	1,024,387
Current liabilities				
Trade and other payables . . .	60,322	61,476	86,835	73,881
Contract liabilities	11,154	7,218	7,401	6,277
Interest-bearing borrowings . .	—	—	136	136
Lease liabilities	33,032	31,327	28,113	30,045

FINANCIAL INFORMATION

	As of December 31,			As of April 30,
	2023	2024	2025	2026
	(RMB in thousands)			
Financial liabilities measured at fair value through profit or loss (“FVPL”)	150	—	—	—
Current taxation	7,480	8,314	6,095	2,840
Total current liabilities	112,138	108,335	128,580	113,179
Net current assets	554,260	660,594	873,137	911,208
Total assets less current liabilities	879,546	937,835	1,046,421	1,095,984
Non-current liabilities				
Lease liabilities	55,348	33,350	19,074	24,095
Deferred tax liabilities	340	1,101	789	765
Total non-current liabilities	55,688	34,451	19,863	24,860
Net assets	823,858	903,384	1,026,558	1,071,124

Property, Plant and Equipment

Our property, plant and equipment consisted of (i) plant and buildings, which are primarily for our offices and research and development, logistics and manufacturing activities; (ii) machinery and equipment, which are primarily for the production of our temperature-control packaging materials and products; (iii) motor vehicles, which are primarily used for logistics services and office operations; (iv) specialized equipment, primarily including VIPs, liquid nitrogen tanks and cooling equipments; (v) office and other equipment; and (vi) construction in progress, primarily related to our depot facilities in Shanghai. The table below sets forth a breakdown of the net carrying amount of our property, plant and equipment as of the dates indicated:

	As of December 31,			As of April 30,
	2023	2024	2025	2026
	(RMB in thousands)			
Plant and buildings	8,220	7,794	7,368	7,226
Machinery and equipment . . .	7,751	5,685	5,145	4,474
Motor vehicles	32,451	24,470	18,785	16,587
Specialized equipment	37,553	32,054	24,409	24,691
Office and other equipment . .	2,051	1,575	1,339	1,339
Construction in progress . . .	8,649	—	—	8,793
Total	96,675	71,578	57,046	63,110

FINANCIAL INFORMATION

Our property, plant and equipment decreased from RMB96.7 million as of December 31, 2023 to RMB71.6 million as of December 31, 2024, and further decreased to RMB57.0 million as of December 31, 2025, primarily due to regular depreciation and disposal of vehicles and equipment in the ordinary course of business. It then increased to RMB63.1 million as of April 30, 2026, primarily due to an increase of RMB8.8 million in construction in progress resulting from our purchase of production lines for manufacturing temperature-control products.

Right-of-Use Assets

Our right-of-use assets represented the carrying amounts of plant and buildings and motor vehicles. Our right-of-use assets decreased from RMB88.4 million as of December 31, 2023 to RMB63.2 million as of December 31, 2024 and further decreased to RMB46.4 million as of December 31, 2025, primarily due to the regular depreciation of right-of-use assets and the decreased leases for plant and buildings. It then increased to RMB52.5 million as of April 30, 2026, primarily due to the newly leased warehouses.

Intangible Assets

Our intangible assets included software and vehicle license plates. Our intangible assets remained relatively stable at RMB6.4 million, RMB6.5 million, RMB6.5 million and RMB6.4 million as of December 31, 2023, 2024, 2025 and April 30, 2026, respectively.

Goodwill

We recorded goodwill of RMB13.8 million, RMB13.8 million, RMB13.8 million and RMB13.8 million as of December 31, 2023, 2024, 2025 and April 30, 2026, respectively. The carrying amount of goodwill was allocated to cash-generating units (“CGUs”) including Beijing MED-LOGISTICS Co., Ltd. (“Med-Logistics”) and other CGU without significant goodwill. The following sets forth details of the carrying amount of goodwill allocated to each CGU as of the dates indicated:

	As of December 31,			As of April 30,
	2023	2024	2025	2026
	(RMB in thousands)			
Med-Logistics	12,267	12,267	12,267	12,267
Other unit without significant goodwill	1,486	1,486	1,486	1,486
Total	13,753	13,753	13,753	13,753

Goodwill is tested by our management for impairment annually. The recoverable amount of the CGUs has been determined based on a value-in-use (“VIU”) calculation. The recoverable amount of a CGU is the greater of its VIU and its fair value less costs of disposal.

FINANCIAL INFORMATION

The VIU is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU.

We engaged an independent third-party valuer for the calculation of the recoverable amount of Med-Logistics CGU, and such calculations use cash flow projections based on financial budgets approved by the management covering a five-year period. The discount rate used is pre-tax and reflects specific risks relating to the relevant industry, the CGU itself and macro-environment. The key assumptions used in estimating the recoverable amount are as follows:

	As of December 31,			As of April 30,
	2023	2024	2025	2026
Annual revenue growth rate during the forecast period	7.50%~20.00%	10.00%~35.46%	2.00%~29.24%	2.00%~29.24%
Gross profit margin	14.34%~25.13%	3.67%~31.99%	16.50%~30.95%	16.50%~30.95%
Growth rate beyond the forecast period	2%	2%	2%	2%
Pre-tax discount rate	13.93%	13.57%	13.83%	13.83%

Accordingly, the headroom calculated based on the recoverable amounts deducting the carrying amount of the Med-Logistics CGU was RMB3.6 million, RMB4.9 million, RMB9.6 million and RMB9.6 million as of December 31, 2023, 2024, 2025 and April 30, 2026, respectively.

Our management has undertaken a sensitivity analysis on the impairment of goodwill of Med-Logistics CGU. The following table sets out the hypothetical changes to (i) the annual growth rate during the five-year forecast period; (ii) the gross margin rate; and (iii) the discount rate, which, if applied individually, would have eliminated the remaining headroom as of December 31, 2023, 2024, 2025 and April 30, 2026, respectively:

	As of December 31,			As of April 30,
	2023	2024	2025	2026
Annual growth rate of revenue during the five-year forecast period	(3.12%)	(4.44%)	(9.81)%	(9.81)%
Gross margin rate	(1.99%)	(3.56%)	(6.01)%	(6.01)%
Pre-tax discount rate	1.35%	1.77%	3.91%	3.91%

FINANCIAL INFORMATION

We have performed impairment test on goodwill as of December 31, 2023, 2024, 2025 and April 30, 2026. The recoverable amount of Med-Logistics CGU based on the VIU calculations was higher than its carrying amount as of December 31, 2023, 2024, 2025 and April 30, 2026. With regard to the assessment of the VIU of Med-Logistics CGU, our directors believe that any reasonably possible change in any of the above key assumptions would not cause the carrying value, including goodwill, of the relevant CGU to exceed the recoverable amounts. As of April 30, 2026, our management has considered and assessed available internal and external sources of information and has not identified any indications that an impairment loss of goodwill may have occurred.

Other Financial Assets

Our other financial assets represent the certificate of deposits, structured deposits and wealth management products with banks. During the Track Record Period, we primarily purchased (i) negotiable certificate of deposits from banks, which was transferable and carried at fixed interest rate of 3.05%-3.10% per annum; and (ii) structured deposits and wealth management products from banks with an expected return rate ranged from 1.45% to 4.5% per annum. Accordingly, we have recorded (i) the non-current portion of certificate of deposits of RMB81.7 million, RMB84.2 million, nil and nil; (ii) the current portion of certificate of deposits of nil, nil, RMB86.6 million and RMB54.5 million, and (iii) structured deposits and wealth management products of nil, RMB1.4 million, RMB5.8 million and RMB436.7 million, respectively, as of December 31, 2023, 2024, 2025 and April 30, 2026.

We have established management systems that specify the approval authority, authorization management, operation processes, financial accounting, supervision and risk control procedures of our wealth management activities, so as to standardize our financial product investments. The types of wealth management products we choose are low-risk products with high safety and good liquidity. Adhering to prudent investment principles, we conduct investment activities with an aim to improve capital utilization efficiency and investment returns on cash assets. Our finance department manages our wealth management portfolio, primarily including the preparation of our annual wealth management plan, handling wealth management products, and conducting daily management and accounting procedures.

Following the [REDACTED], our investments in financial products will be conducted in accordance with the provisions of Chapter 14 of the Listing Rules.

FINANCIAL INFORMATION

Other Non-current Assets

Our other non-current assets primarily included (i) prepayments for property, plant and equipment; and (ii) long-term deferred expense primarily relating to the renovation costs and software operation and maintenance fees. The table below sets forth a breakdown of the other non-current assets as of the dates indicated:

	As of December 31,			As of April 30,
	2023	2024	2025	2026
	(RMB in thousands)			
Prepayments for property, plant and equipment	1,225	260	8,212	6,110
Long-term deferred expense	4,971	4,085	3,385	3,220
Total	6,196	4,345	11,597	9,330

Our other non-current assets decreased from RMB6.2 million as of December 31, 2023 to RMB4.3 million as of December 31, 2024, and then increased to RMB11.6 million as of December 31, 2025, and then decreased to RMB9.3 million as of April 30, 2026. Such fluctuations were primarily attributable to the timing of purchases of property, plant and equipment in line with our operational needs during the relevant periods.

Inventories

Our inventories primarily comprised of (i) raw materials used for the production of our VIPs and PCM packs; (ii) low value consumables, mainly including thermometers; and (iii) finished goods and work in progress, which were our temperature-control products, VIPs and PCM packs. The following table sets forth our inventories as of the dates indicated:

	As of December 31,			As of April 30,
	2023	2024	2025	2026
	(RMB in thousands)			
Raw materials	2,810	3,459	3,681	3,682
Low value consumables	7,603	8,376	8,175	9,221
Work in progress	85	96	54	—
Finished goods	9,239	7,931	7,875	8,239
Total	19,737	19,862	19,785	21,142

FINANCIAL INFORMATION

Our inventories remained relatively stable during the Track Record Period, from RMB19.7 million as of December 31, 2023 to RMB19.9 million as of December 31, 2024, and further to RMB19.8 million as of December 31, 2025 and to RMB21.1 million as of April 30, 2026, respectively.

We have adopted a strict and effective procurement policies, together with a demand-based production model, to ensure that our inventory levels remain healthy and stable. Our inventory turnover days remained relatively stable at 17 days, 17 days, 16 days and 15 days in 2023 and 2024, 2025 and for the four months ended April 30, 2026, respectively. Our inventory turnover days are calculated as the average of the beginning and ending balance of inventories for the year/period divided by the cost of sales for that year/period and multiplied by 365 days for a year or 120 days for the four-month period.

During the Track Record Period, a portion of our inventories had an aging of over one year, amounting to RMB13.9 million, RMB11.8 million, RMB9.2 million and RMB9.6 million as of December 31, 2023, 2024, 2025 and April 30, 2026, respectively. Such inventories primarily consisted of consumables used in the provision of our supply chain services, including reusable thermometers. The following table sets forth an aging analysis of our inventories as of the dates indicated:

	As of December 31,			As of April 30,
	2023	2024	2025	2026
	(RMB in thousands)			
Within 1 year	5,875	8,034	10,618	11,523
Over 1 year	13,862	11,828	9,167	9,619
Total	19,737	19,862	19,785	21,142

As of December 31, 2023, 2024, 2025 and April 30, 2026, we had not made provision for inventories. We measured inventories at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. We review the condition of our inventories regularly and review recoverability and aging of inventories at the end of each year. We assess the recoverability of inventories by comparing their carrying amounts with their net realizable values. In assessing the recoverability of our inventories, we do not solely rely on subsequent sale or disposal, but also consider the nature of the relevant inventory items, their physical condition, whether there is any indication of obsolescence, damage or prolonged idleness, as well as their expected future utilization in our operations. As of December 31, 2023, 2024, 2025 and April 30, 2026, our inventories with aging of over one year primarily consisted of consumables used in the provision of our temperature-control supply chain services, including reusable thermometers. Such reusable thermometers are generally not held primarily for direct sale, do not usually have a shelf life and are repeatedly deployed in our day-to-day service operations. Taking into account the foregoing, together with

FINANCIAL INFORMATION

our regular stocktakes and inventory review procedures, our Directors are of the view that there is no material recoverability issue for our inventories and no inventory provision was required as of December 31, 2023, 2024, 2025 and April 30, 2026.

As of May 31, 2026, RMB2.4 million, or 11.5% of our inventories as of April 30, 2026, had been subsequently sold or disposed.

Trade and Other Receivables

Our trade and other receivables primarily consisted of (i) trade receivables, net of loss allowance, mainly representing the receivables from customers of our temperature-control supply chain services and sales of temperature-control products; (ii) deposits and others, mainly representing rental deposits for premises and vehicle leases; (iii) prepayment to suppliers primarily consisted of advance payment for raw materials procurement, prepaid expenses of vehicle fuel, ETC toll prepayment and insurance premium; and (iv) value-added tax recoverable. The following table sets forth the details of our trade and other receivables as of the dates indicated:

	As of December 31,			As of April 30,
	2023	2024	2025	2026
	(RMB in thousands)			
Trade receivables, net of loss allowance	157,868	192,277	226,110	263,812
Deposits and others	17,991	17,695	22,344	24,925
Prepayment to suppliers	5,408	4,519	4,506	6,882
Bills receivable measured at amortized cost	—	1,804	2,159	704
Value-added tax recoverable .	10,826	12,393	1,669	1,109
Capitalized [REDACTED] expenses .	—	—	[REDACTED]	[REDACTED]
Total	192,093	228,688	258,407	301,209

Our trade and other receivables increased from RMB192.1 million as of December 31, 2023 to RMB228.7 million as of December 31, 2024, and further increased to RMB258.4 million as of December 31, 2025 and further increased to RMB301.2 million as of April 30, 2026, primarily due to the increase in trade receivables which was in line with our overall business growth.

Our trade and bills receivables primarily arose from our temperature-control supply chain services provided to customers. We generally grant a credit period of 10 to 90 days to our customers. Our trade and bills receivables turnover days remained relatively stable at 98 days in 2023 and 2024, and slightly increased to 106 days in 2025 and then increased to 115 days for the four months ended April 30, 2026, primarily due to the increased balance of trade and bills receivables attributable to our business growth. Our trade and bills receivables turnover

FINANCIAL INFORMATION

days are calculated as the average of the beginning and ending balance of trade and bills receivables for the year/period divided by the revenue for that year/period and multiplied by 365 days or 120 days for the four-month period.

The following table sets forth an aging analysis of our trade receivables as of the dates indicated based on the revenue recognition date:

	As of December 31,			As of April 30,
	2023	2024	2025	2026
	<i>(RMB in thousands)</i>			
Within one year	158,025	193,774	225,701	265,888
More than one year and within two years	3,180	2,197	3,889	2,472
More than two years and within three years	169	1,270	193	221
More than three years	3	86	—	—
	161,377	197,327	229,783	268,581
Less: loss allowance	(3,509)	(5,050)	(3,673)	(4,769)
Total	157,868	192,277	226,110	263,812

As of December 31, 2023, 2024, 2025 and April 30, 2026, we recorded loss allowance for trade receivables of RMB3.5 million, RMB5.1 million, RMB3.7 million and RMB4.8 million, respectively. We have established a credit risk management policy under which individual credit evaluations are performed on our customers requiring credit over a certain amount. We manage credit risk through established credit control procedures, including customer credit evaluation, ongoing monitoring of outstanding balances and impairment assessment under the expected credit loss model. We assess the recoverability of our trade receivables with reference to, among other things, their aging profile, historical settlement pattern, the credit quality and financial background of the relevant customers, and whether there are any specific collection issues, disputes or adverse developments. As of April 30, 2026, substantially all of our trade receivables were aged within one year. During the Track Record Period, we did not experience any material collection dispute or default from our customers. Taking into account the foregoing, and our expected credit loss assessment, our Directors are of the view that there is no material recoverability issue in respect of our trade receivables and that the loss allowance made for trade receivables was sufficient as of December 31, 2023, 2024, 2025 and April 30, 2026. For credit risk of our trade receivable, please refer to Note 27(a) to the Accountants’ Report set out in Appendix I to this document.

As of May 31, 2026, RMB55.2 million, or 20.9% of our trade receivables as of April 30, 2026, had been settled.

FINANCIAL INFORMATION

Restricted Cash

We had restricted cash of RMB4.0 million, RMB4.0 million, RMB5.7 million and RMB3.8 million as of December 31, 2023, 2024, 2025 and April 30, 2026, which mainly represented the amount of security deposits related to the provision of cross-boarder services.

Trade and other Payables

Our trade and other payables primarily consisted of (i) trade payables, mainly representing amounts due to suppliers for supplier chain services, raw materials, and supporting consumables; (ii) accrued payroll, welfare and bonus relating to employee compensation; (iii) value-added tax (“VAT”) and other tax payables; (iv) [REDACTED] expense payable; and (v) others.

	As of December 31,			As of April 30,
	2023	2024	2025	2026
	(RMB in thousands)			
Trade payables	25,400	25,323	34,333	35,040
Accrued payroll, welfare and bonus	29,818	31,207	37,160	20,873
VAT and other tax payables .	940	737	2,512	2,453
Payables related to share- based payments	1,194	—	—	—
[REDACTED] expense payable	—	—	[REDACTED]	[REDACTED]
Others	2,970	4,209	4,166	3,591
Total	60,322	61,476	86,835	73,881

Our trade payables remained relatively stable at RMB25.4 million as of December 31, 2023 and RMB25.3 million as of December 31, 2024, and then increased to RMB34.3 million and RMB35.0 million as of December 31, 2025, and April 30, 2026, respectively. Such increase was primarily due to the increased procurement from suppliers for supply chain services, raw materials, and supporting consumables, in line with our business growth.

Our trade payables turnover days remained relatively stable at 23 days, 21 days, 24 days and 26 days in 2023, 2024, 2025 and for the four months ended April 30, 2026. Our trade payables turnover days are calculated as the average of the beginning and ending balance of trade payables for the year/period divided by cost of sales for that year/period and multiplied by 365 days or 120 days for the four-month period.

FINANCIAL INFORMATION

The following table sets forth an aging analysis of our trade payables as of the dates indicated based on the invoice date:

	As of December 31,			As of April 30,
	2023	2024	2025	2026
	(RMB in thousands)			
Within one year	25,221	24,745	33,950	34,667
More than one year and within two years	105	490	289	279
More than two years but within three years	1	15	8	8
More than three years	73	73	86	86
Total	25,400	25,323	34,333	35,040

As of May 31, 2026, RMB18.6 million, or 53.1% of our trade payables as of April 30, 2026, had been settled.

Contract Liabilities

Our contract liabilities primarily arose from advance payments received from customers in relation to our temperature-control storage service under our clinical trial supply chain services. We recorded contract liabilities of RMB11.2 million, RMB7.2 million, RMB7.4 million and RMB6.3 million as of December 31, 2023, 2024, 2025 and April 30, 2026, respectively. Changes in our contract liabilities reflected the progress of our service fulfillment.

LIQUIDITY AND CAPITAL RESOURCES

Our primary uses of cash are to fund the daily operations of our business. During the Track Record Period, we financed our capital expenditures and working capital requirements principally with cash generated from our operations. Going forward, we believe that our liquidity requirements will be satisfied with a combination of cash flows generated from our operating activities, the net [REDACTED] from the [REDACTED], and other future equity or debt financings. As of December 31, 2023, 2024, 2025 and April 30, 2026, we had cash and cash equivalents of RMB450.6 million, RMB514.9 million, RMB625.4 million and RMB207.1 million, respectively, and restricted cash of RMB4.0 million, RMB4.0 million, RMB5.7 million and RMB3.8 million as of the same respective dates.

FINANCIAL INFORMATION

Net Current Assets

	As of December 31,			As of	As of
	2023	2024	2025	April 30,	May 31,
				2026	2026
					(unaudited)
					(RMB in thousands)
Current assets					
Inventories	19,737	19,862	19,785	21,142	22,005
Trade and other					
receivables	192,093	228,688	258,407	301,209	307,283
Other financial					
assets	–	1,444	92,404	491,140	397,184
Restricted cash	4,003	4,003	5,745	3,817	3,810
Cash and cash					
equivalents	450,565	514,932	625,376	207,079	305,661
Total current assets .	666,398	768,929	1,001,717	1,024,387	1,035,943
Current liabilities					
Trade and other					
payables	60,322	61,476	86,835	73,881	76,419
Contract liabilities . .	11,154	7,218	7,401	6,277	6,056
Interest-bearing					
borrowings	–	–	136	136	136
Lease liabilities	33,032	31,327	28,113	30,045	30,041
Financial liabilities					
measured at fair					
value through					
profit or loss					
(“FVPL”)	150	–	–	–	–
Current taxation	7,480	8,314	6,095	2,840	6,715
Total current					
 liabilities	112,138	108,335	128,580	113,179	119,367
Net current assets . .	554,260	660,594	873,137	911,208	916,576

Our net current assets increased from RMB554.3 million as of December 31, 2023 to RMB660.6 million as of December 31, 2024, primarily due to (i) an increase of RMB64.4 million in cash and cash equivalents; and (ii) an increase of RMB36.6 million in trade and other receivables as a result of our overall business growth.

FINANCIAL INFORMATION

Our net current assets increased from RMB660.6 million as of December 31, 2024 to RMB873.1 million as of December 31, 2025, primarily due to (i) an increase of RMB29.7 million in trade and other receivables, primarily attributable to our business growth; (ii) an increase of RMB91.0 million in other financial assets resulting from our purchase of structured deposits and wealth management products; and (iii) an increase of RMB110.4 million in cash and cash equivalents.

Our net current assets increased from RMB873.1 million as of December 31, 2025 to RMB911.2 million as of April 30, 2026, primarily due to an increase of RMB398.7 million in other financial assets resulting from our purchase of structured deposits and wealth management products and a decrease of RMB13.0 million in trade and other payables, partially offset by a decrease of RMB418.3 million in cash and cash equivalents for our purchase of structured deposits and wealth management products.

Our net current assets increased from RMB911.2 million as of April 30, 2026 to RMB916.6 million as of May 31, 2026, primarily due to an increase of RMB98.6 million in cash and cash equivalents, partially offset by a decrease of RMB94.0 million in other financial assets resulting from the redemption of our structured deposits and wealth management products.

Taking into account our net current assets status, the financial resources available to us, including cash flows from operating activities, cash and cash equivalents at the end of the Track Record Period and the estimated net [REDACTED] of the [REDACTED], the Directors are of the view that we will have sufficient funds to meet our working capital requirements and financial requirements for capital expenditure for at least the next 12 months from the date of this document.

Cash Flows

The following table sets forth our cash flows for the periods indicated:

	For the Year ended December 31,			For the Four Months ended April 30,	
	2023	2024	2025	2025	2026
	(unaudited)				
	(RMB in thousands)				
Net cash generated from					
operating activities	171,139	139,303	183,894	26,984	230
Net cash used in investing					
activities	(105,538)	(16,107)	(10,382)	(404,667)	(405,538)
Net cash used in					
financing activities	(40,626)	(58,186)	(62,748)	(10,750)	(11,916)

FINANCIAL INFORMATION

	For the Year ended December 31,			For the Four Months ended April 30,	
	2023	2024	2025	2025	2026
				<i>(unaudited)</i>	
				<i>(RMB in thousands)</i>	
Net increase in cash and cash equivalents	24,975	65,010	110,764	(388,433)	(417,224)
Effect of foreign exchange rate changes .	700	(643)	(320)	632	(1,073)
Cash and cash equivalents at the beginning of the year/period	424,890	450,565	514,932	514,932	625,376
Cash and cash equivalents at the end of the year/period	450,565	514,932	625,376	127,131	207,079

Net Cash Generated from Operating Activities

Net cash generated from operating activities was RMB0.2 million for the four months ended April 30, 2026. The difference between the operating cash inflow and the profit before taxation of RMB50.2 million was the result of adding back non-cash items, which primarily consisted of a depreciation of RMB18.6 million; partially offset by additional consumption of working capitals, including an increase in trade and other receivables of RMB42.8 million, together with the income tax paid of RMB10.2 million.

Net cash generated from operating activities was RMB183.9 million in 2025. The difference between the operating cash inflow and the profit before taxation of RMB159.8 million was the result of adding back non-cash items, which primarily consisted of a depreciation of RMB64.1 million; partially offset by additional consumption of working capitals, including an increase in trade and other receivables of RMB31.5 million, together with the income tax paid of RMB27.7 million.

Net cash generated from operating activities was RMB139.3 million in 2024. The difference between the operating cash inflow and the profit before taxation of RMB44.5 million was the result of adding back non-cash items, which primarily consisted of a depreciation of RMB74.4 million and share-based payments of RMB72.1 million; and partially offset by additional consumption of working capitals, including an increase in trade and other receivables of RMB36.4 million, together with the income tax paid of RMB17.9 million.

FINANCIAL INFORMATION

Net cash generated from operating activities was RMB171.1 million in 2023. The difference between the operating cash inflow and the profit before taxation of RMB103.3 million was the result of adding back non-cash items, which primarily consisted of a depreciation of RMB65.4 million; and additional released working capital, including an increase in trade and other payables of RMB16.7 million, partially offset by the income tax paid of RMB17.3 million.

Net Cash Used in Investing Activities

Net cash used in investing activities for the four months ended April 30, 2026 was RMB405.5 million, primarily attributable to acquisition of other financial assets with maturity period over three months of RMB160.0 million, acquisition of property, plant and equipment and other long-term assets of RMB9.8 million, partially offset by proceeds from disposal of other financial assets with maturity period over three months of RMB42.8 million.

Net cash used in investing activities in 2025 was RMB10.4 million, primarily attributable to acquisition of other financial assets with maturity period over three months of RMB290.0 million, acquisition of property, plant and equipment and other long-term assets of RMB15.4 million, partially offset by proceeds from disposal of other financial assets with maturity period over three months of RMB291.7 million.

Net cash used in investing activities in 2024 was RMB16.1 million, primarily attributable to acquisition of other financial assets with maturity period over three months of RMB271.3 million and acquisition of property, plant and equipment and other long-term assets of RMB22.1 million, partially offset by proceeds from disposal of other financial assets with maturity period over three months of RMB274.3 million.

Net cash used in investing activities in 2023 was RMB105.5 million, primarily attributable to acquisition of other financial assets with maturity period over three months of RMB230.0 million and acquisition of property, plant and equipment and other long-term assets of RMB29.6 million, partially offset by proceeds from disposal of other financial assets with maturity period over three months of RMB151.4 million.

Net Cash Used in Financing Activities

Net cash used in financing activities for the four months ended April 30, 2026 was RMB11.9 million, primarily attributable to lease payments of RMB11.9 million.

Net cash used in financing activities in 2025 was RMB62.7 million, primarily attributable to lease payments of RMB42.4 million and dividends paid of RMB20.0 million.

Net cash used in financing activities in 2024 was RMB58.2 million, primarily attributable to lease payments of RMB38.1 million and dividends paid of RMB20.1 million.

FINANCIAL INFORMATION

Net cash used in financing activities in 2023 was RMB40.6 million attributable to lease payments of RMB40.6 million.

INDEBTEDNESS

Our Directors confirm that, there was no material covenant on any of our outstanding debt, and there was no breach of any covenant during the Track Record Period and up to the Latest Practicable Date. Our Directors further confirm that we did not experience any difficulty in obtaining bank loans and other borrowings, default in payment of bank loans and other borrowings or breach of covenants during the Track Record Period and up to the Latest Practicable Date.

As of May 31, 2026, being the most recent practicable date for purposes of the indebtedness disclosures in this document, except as otherwise disclosed in this document, we did not have any outstanding mortgages, charges, debentures, other issued debt capital, bank overdrafts, borrowings, liabilities under acceptance or other similar indebtedness, hire purchase commitments, guarantees or other material contingent liabilities. Since May 31, 2026, and up to the date of this document, there had been no material change to our indebtedness. The following table sets forth the breakdown of our indebtedness as of the dates indicated:

	As of December 31,			As of	As of
	2023	2024	2025	April 30,	May 31,
				2026	2026
					(unaudited)
					(RMB in thousands)
Current					
Interest-bearing					
borrowings	–	–	136	136	136
Lease liabilities	33,032	31,327	28,113	30,045	30,041
Non-current					
Lease liabilities	55,348	33,350	19,074	24,095	20,502
Total	88,380	64,677	47,323	54,276	50,679

Interest-bearing Borrowings

Our interest-bearing borrowings during the Track Record Period were primarily used for business development and working capital purpose. During the Track Record Period, the effective interest rate for our interest-bearing borrowings was 2.3%. As of May 31, 2026, we had interest-bearing borrowings of RMB0.1 million. As of May 31, 2026, we had unutilized bank facilities of RMB199.9 million.

FINANCIAL INFORMATION

Lease Liabilities

During the Track Record Period, our lease liabilities were primarily in relation to our lease of plants and buildings used in our operations and our lease of motor vehicles. We recorded lease liabilities in aggregate of RMB88.4 million, RMB64.7 million, RMB47.2 million, RMB54.1 million and RMB50.5 million as of December 31, 2023, 2024 and 2025, April 30, 2026 and May 31 2026, respectively.

CAPITAL EXPENDITURES

We regularly incur capital expenditures to expand our operations, upgrade our facilities, increase our operating efficiency and enhance our R&D capabilities. Our capital expenditures primarily consisted of expenditures on acquisition of property, plant and equipment and other long-term assets during the Track Record Period, which amounted to RMB29.6 million, RMB22.1 million, RMB15.4 million and RMB9.8 million, in 2023, 2024, 2025 and for the four months ended April 30, 2026, respectively.

CAPITAL COMMITMENTS

As of December 31, 2023, 2024, 2025 and April 30, 2026, we had capital commitments of RMB3.2 million, RMB0.8 million, RMB13.5 million and RMB18.4 million, respectively, primarily in connection with our acquisition of property, plant and equipment, intangible assets and other long-term assets.

CONTINGENT LIABILITIES

As of December 31, 2023, 2024, 2025 and April 30, 2026, we did not have any material contingent liabilities. We confirm that as of the Latest Practicable Date, there had been no material changes or arrangements to our contingent liabilities.

OFF-BALANCE SHEET COMMITMENTS AND ARRANGEMENTS

As of the Latest Practicable Date, we had not entered into any off-balance sheet transactions.

KEY FINANCIAL RATIOS

The table below sets forth the key financial ratios of our Group for the periods or as of the dates indicated:

	For the Year ended/As of December 31,			For the Four Months ended/As of April 30,
	2023	2024	2025	2026
Current ratio ⁽¹⁾	5.9	7.1	7.8	9.1
Quick ratio ⁽²⁾	5.8	6.9	7.6	8.9

FINANCIAL INFORMATION

	For the Year ended/As of December 31,			For the Four Months ended/As of April 30,
	2023	2024	2025	2026
Net profit margin ⁽³⁾	15.0%	4.0%	19.1%	17.6%
Adjusted net profit margin (non-IFRS measure) ⁽⁴⁾ . . .	15.9%	15.4%	20.9%	21.7%
Return on assets ⁽⁵⁾	9.8%	2.6%	12.5%	11.4%
Return on equity ⁽⁶⁾	11.8%	3.1%	14.4%	12.9%

Notes:

- (1) Current ratio represents current assets divided by current liabilities as of the same date.
- (2) Quick ratio represents current assets less inventories, divided by current liabilities as of the same date.
- (3) Net profit margin is calculated using the net profit divided by revenues for a given period.
- (4) Adjusted net profit margin (non-IFRS measure) is calculated using the adjusted net profit (Non-IFRS measure) divided by revenues for a given period. Please see “— Non-IFRS Measure” for details.
- (5) Return on assets equals profit (on an actual basis for 2023, 2024 and 2025, and an annualized basis for the four months ended April 30, 2026) for the year/period divided by the average of the opening and closing balances of total assets for the same year/period and multiplied by 100%.
- (6) Return on equity equals profit (on an actual basis for 2023, 2024 and 2025, and an annualized basis for the four months ended April 30, 2026) for the year/period divided by the average of the opening and closing balances of total equity for the same year/period and multiplied by 100%.

RELATED PARTY TRANSACTIONS

We enter into transactions with our related parties from time to time. Our Directors are of the view that each of the related party transactions set out in Note 29 to the Accountants’ Report included in Appendix I to this document was conducted in the ordinary course of business on an arm’s length basis and with normal commercial terms between the relevant parties. Our Directors are also of the view that our related party transactions during the Track Record Period would not distort our track record results or cause our historical results to become non-reflective of our future performance.

As of December 31, 2023, 2024, 2025 and April 30, 2026, our outstanding balances due from related parties amounted to RMB1.1 million, RMB0.8 million, RMB3.0 million and RMB4.5 million, respectively. All of our balances with related parties were trade in nature during the Track Record Period.

MARKET RISK DISCLOSURE

We are exposed to various market risks, including credit, liquidity, interest rate and currency risks arising from the normal course of our business. For details, see Note 27 to the Accountants’ Report set out in Appendix I to this document.

FINANCIAL INFORMATION

DIVIDEND

During the Track Record Period, our dividends paid in respective of the approved dividends amounted to nil, RMB20.1 million, RMB20.0 million and nil in 2023, 2024, 2025 and for the four months ended April 30, 2026, respectively. As of the Latest Practicable Date, all of such dividends declared during the Track Record Period had been settled in full. See Note 26(b) to the Accountant’s Report in Appendix I to this document for details. In June 2026, as approved at our Shareholders’ general meeting held on June 12, 2026, we declared and paid a dividend of RMB30.6 million to our existing Shareholders.

Pursuant to our Articles of Association, our Board may declare dividends in the future after taking into account our results of operations, financial condition, cash requirements and availability and other factors as it may deem relevant at such time. As of the Latest Practicable Date, we did not have a formal dividend policy or a fixed dividend distribution ratio. Any declaration and payment as well as the amount of dividends will be subject to our constitutional documents, applicable PRC Law and approval by our Shareholders. We may provide our Shareholders with interim or annual dividends as the Board deems appropriate, subject to the discretion of our Directors in accordance with our Articles of Association and the applicable laws and regulations in the PRC and Hong Kong. Our future declarations of dividends may not be in line with our historical declaration of dividends and will be subject to the approval of our Shareholders.

DISTRIBUTABLE RESERVES

As of April 30, 2026, we had distributable reserves comprising the retained profits of our Company amounting to RMB29.9 million, which were available for distribution.

[REDACTED] EXPENSES

[REDACTED] expenses to be borne by us are estimated to be approximately HK\$[REDACTED] million (based on an [REDACTED] of HK\$[REDACTED] per H Share), representing approximately [REDACTED]% of the estimated gross [REDACTED] from the [REDACTED] assuming no Shares are issued pursuant to the [REDACTED]. The [REDACTED] expenses consist of (i) [REDACTED] expenses, including [REDACTED], of approximately HK\$[REDACTED] million, and (ii) non-[REDACTED] expenses of approximately HK\$[REDACTED] million, comprising (a) fees and expenses of our legal advisors and reporting accountants of approximately HK\$[REDACTED] million, and (b) other fees and expenses of approximately HK\$[REDACTED] million. The [REDACTED] expenses above are the latest practicable estimate for reference only, and the actual amount may differ from this estimate. During the Track Record Period, we incurred [REDACTED] expenses in connection with the [REDACTED] of HK\$[REDACTED] million, of which (i) HK\$[REDACTED] million was charged to the consolidated statements of profit or loss, and (ii) HK\$[REDACTED] million was directly attributable to the issue of our H Shares and is expected to be deducted from equity upon the [REDACTED]. Subsequent to the Track Record Period, approximately HK\$[REDACTED] million of the [REDACTED] expenses is expected

FINANCIAL INFORMATION

to be charged to profit or loss, and approximately HK\$[REDACTED] million directly attributable to the issue of the H Shares is expected to be deducted from equity upon the completion of the [REDACTED].

UNAUDITED [REDACTED] STATEMENT OF ADJUSTED NET TANGIBLE ASSETS

For details, see “Appendix II — Unaudited [REDACTED] Financial Information.”

NO MATERIAL ADVERSE CHANGE

Our Directors confirm that up to the date of this document, other than as disclosed under the “Recent Development and No Material Adverse Change” in the “Summary” section in this document, there had been no material adverse change in our financial, operational or prospects since April 30, 2026, being the latest balance sheet date of our consolidated financial statements as set out in the Accountants’ Report included in Appendix I to this document.

DISCLOSURE UNDER RULES 13.13 TO 13.19 OF THE LISTING RULES

Our Directors have confirmed that, as of the Latest Practicable Date, there was no circumstance that would give rise to a disclosure requirement under Rules 13.13 to 13.19 of the Listing Rules.